Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-Target CAR-T (Mesothelin/Claudin 18.2) in Advanced Pancreatic Cancer
NCT07066995Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of mesothelin CAR-T cells, Claudin18.2 CAR-T cells in pancreatic ductal adenocarcinoma (PDAC), sponsored by Essen BioTech. Started Apr 2025; status: recruiting.
02
Drugs
mesothelin CAR-T cellsClaudin18.2 CAR-T cells
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07066995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066995.